Skip to main content
IC

Paul Mattels

Stock Analyst at Stifel

(n/a)
# 4,471
Out of 4,829 analysts
4
Total ratings
n/a
Success rate
-37.85%
Average return
Main Sectors:
Healthcare
Top Industries:
Biotechnology

Stocks Rated by Paul Mattels

Denali Therapeutics
Dec 16, 2024
Upgrades: Buy
Price Target: $37
Current: $14.80
Upside: +150.00%
Alector
Feb 19, 2020
Initiates: Buy
Price Target: $44
Current: $1.20
Upside: +3,566.67%